May 15, 2013.
Sophia Antipolis, France.
Nicox S.A. (NYSE Euronext Paris: COX) today reports financial results for the first three months of 2013 and provides an overview of its activities.
“We are encouraged by the progress made this quarter in growing Nicox as a new international ophthalmic company. We entered into an exclusive supply and distribution agreement for an innovative line of eye care products planned to be launched from the end of the year and our partner Bausch + Lomb initiated the phase 3 programme of the latanoprostene bunod as planned. These two important achievements represent new steps in our plan to create a portfolio of therapeutics and diagnostics which will support Nicox’s expansion in the ophthalmic markets of Europe and the United States”, said Michele Garufi, Chief Executive Officer of Nicox.
Download the pdf file to read the full press release.